Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors
Defence Therapeutics has appointed Dr. Svetlana Selivanova to its board of directors. Dr. Selivanova is a radiochemist with over 20 years of experience in radiopharmaceutical development and currently serves as Section Head for Radiochemistry and Medical Applications at Canadian Nuclear Laboratories. She holds key positions in professional societies and serves as an expert-consultant for international organizations. The appointment aligns with Defence's strategy to develop radio-immuno-conjugates using their Accum® platform. The company granted her 100,000 incentive stock options, exercisable at 60 cents per share. Dr. Raimar Lobenberg is stepping down from the board.
Defence Therapeutics ha nominato la Dott.ssa Svetlana Selivanova nel suo consiglio di amministrazione. La Dott.ssa Selivanova è una radiochimica con oltre 20 anni di esperienza nello sviluppo di radiofarmaci e attualmente ricopre il ruolo di Capo Sezione per la Radiochimica e le Applicazioni Mediche presso i Canadian Nuclear Laboratories. Detiene anche posizioni chiave in società professionali e funge da esperta-consulente per organizzazioni internazionali. Questa nomina si allinea con la strategia di Defence per sviluppare radio-immuno-coniugati utilizzando la loro piattaforma Accum®. L'azienda le ha concesso 100.000 opzioni su azioni incentivanti, esercitabili a 60 centesimi per azione. Il Dott. Raimar Lobenberg si dimette dal consiglio.
Defence Therapeutics ha nombrado a la Dra. Svetlana Selivanova en su junta directiva. La Dra. Selivanova es una radioquímica con más de 20 años de experiencia en el desarrollo de radiofármacos y actualmente se desempeña como Jefa de Sección de Radioquímica y Aplicaciones Médicas en los Laboratorios Nucleares Canadienses. Ocupa puestos clave en sociedades profesionales y actúa como consultora experta para organizaciones internacionales. Esta designación se alinea con la estrategia de Defence para desarrollar radio-inmuno-conjugados utilizando su plataforma Accum®. La empresa le ha otorgado 100,000 opciones de acciones de incentivo, que se pueden ejercer a 60 centavos por acción. El Dr. Raimar Lobenberg renuncia a la junta.
Defence Therapeutics는 Svetlana Selivanova 박사를 이사회에 임명했습니다. Selivanova 박사는 방사성 의약품 개발 분야에서 20년 이상의 경험을 가진 방사화학자로 현재 캐나다 원자력 연구소의 방사화학 및 의학 응용 섹션 책임자로 근무하고 있습니다. 그녀는 전문 협회의 주요 직책을 맡고 있으며 국제기구의 전문가 자문 역할을 수행하고 있습니다. 이번 임명은 Defence의 Accum® 플랫폼을 이용하여 방사면역결합체를 개발하려는 전략과 일치합니다. 회사는 그녀에게 100,000개의 인센티브 주식 옵션을 부여하였으며, 주당 60센트에 행사할 수 있습니다. Raimar Lobenberg 박사는 이사회에서 물러납니다.
Defence Therapeutics a nommé Dr Svetlana Selivanova au sein de son conseil d'administration. Dr Selivanova est une radiochimiste avec plus de 20 ans d'expérience dans le développement de radiopharmaceutiques et elle occupe actuellement le poste de responsable de la section de Radiochimie et des Applications Médicales à Canadian Nuclear Laboratories. Elle occupe des postes clés dans des sociétés professionnelles et agit en tant que consultante experte pour des organisations internationales. Cette nomination s'inscrit dans la stratégie de Defence visant à développer des radio-immuno-conjugués en utilisant leur plateforme Accum®. L'entreprise lui a accordé 100 000 options d'actions incitatives, exerçables à 60 cents par action. Dr Raimar Lobenberg démissionne du conseil.
Defence Therapeutics hat Dr. Svetlana Selivanova in seinen Vorstand berufen. Dr. Selivanova ist eine Radiochemikerin mit über 20 Jahren Erfahrung in der Entwicklung von Radiopharmazeutika und leitet derzeit die Abteilung für Radiochemie und medizinische Anwendungen bei den Canadian Nuclear Laboratories. Sie bekleidet wichtige Positionen in Fachgesellschaften und arbeitet als Expertin für internationale Organisationen. Die Ernennung steht im Einklang mit der Strategie von Defence, radio-immuno-konjugate mit ihrer Accum®-Plattform zu entwickeln. Das Unternehmen hat ihr 100.000 Anreizaktienoptionen gewährt, die zu einem Preis von 60 Cent pro Aktie ausgeübt werden können. Dr. Raimar Lobenberg tritt aus dem Vorstand zurück.
- Appointment of highly qualified radiopharmaceutical expert strengthens company's expertise in key development area
- Strategic alignment with company's focus on radio-immuno-conjugates development
- Dr. Selivanova brings valuable international connections and industry leadership positions
- Board member turnover with Dr. Lobenberg's departure
- Dilutive effect of 100,000 new stock options issued
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Svetlana Selivanova has joined the board of directors, effective immediately.
Dr. Svetlana Selivanova is radiochemist with more than 20 years of experience in the development of radiopharmaceuticals from early R&D to first-in-human clinical trials. She holds MSc in chemistry and PhD in radiopharmaceutical chemistry and radiobiology. Currently, she is Section Head for Radiochemistry and Medical Applications at Canadian Nuclear Laboratories (CNL) and adjunct professor at the Faculty of Pharmacy, Université Laval. Before joining CNL, she held senior positions, both in research and management, at CHU de Quebec-Université Laval, Sherbrooke University Hospital, and at the Center for Radiopharmaceutical Sciences of ETH Zurich (Switzerland).
Dr. Selivanova is an active member of several professional societies, currently serving as Executive Member of the Canadian Association of Radiopharmaceutical Scientists, President of the SNMMI Radiopharmaceutical Sciences Council, and member of the SNMMI Committee on Radiopharmaceuticals. Internationally, she serves as expert-consultant for the International Atomic Energy Agency and the European Research Council. Dr. Selivanova research interests are in the development and translation of novel radiopharmaceuticals from bench to clinics and in nuclear imaging as a tool for studying biochemical pathways in vivo. Among major accomplishments are her contribution to R&D and translation effort for the production of technetium-99m with cyclotron, and implementation of investigational prostate cancer radiopharmaceutical targeting prostate-specific membrane antigen.
"We are proud that Dr. Svetlana Selivanova is joining our board of directors. She is a very strong addition to our Company. Defence's strategy is to develop radio-immuno-conjugates using our Accum® platform. Dr. Selivanova has extensive knowledge and experience in this field and will strengthen and accelerate our radiopharmaceuticals programs," mentioned Sébastien Plouffe, President, CEO and Founder of Defence Therapeutics.
"I am honored to join Defence Therapeutics board of directors. I believe that Defence's Accum® technology platform has a great potential for the development of targeted radiopharmaceutical therapies," mentioned Dr. Svetlana Selivanova.
The Company has granted 100,000 incentive stock options to Svetlana Selivanova, in accordance with the terms and conditions of Defence's stock option plan. Each stock option vests immediately and is exercisable at a price of 60 cents per share for a period of three years from the grant date.
The company would also like to mention that Dr. Raimar Lobenberg is stepping down from the board of directors. The company would like to thank Dr. Lobenberg for its valuable contributions to the board of directors.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229721
FAQ
What is Dr. Svetlana Selivanova's role at Defence Therapeutics (DTCFF)?
What stock options did Defence Therapeutics (DTCFF) grant to Dr. Selivanova?
How will Dr. Selivanova's appointment impact Defence Therapeutics' (DTCFF) development strategy?
